Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.…
Taysha Gene Therapies, Inc. Q3 2026 Earnings Call Summary
Taysha Gene Therapies (NASDAQ: TSHA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 99 employees.
The shares were at 3.720 USD on 20 November 2026, down 5.1% over 52 weeks. Its 52-week range is 3.455 USD to 7.300 USD: the price is 49.0% below the high and 7.7% above the low.
Its market capitalisation is 1.21B USD.
Taysha Gene Therapies reports return on equity of -44.1%.
It holds more cash than debt, a net cash position of 368.24M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 13 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 13.00 USD is 249.5% above the current price. The next earnings report is expected on 25 February 2027.